NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 119 filers reported holding NURIX THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $411,298 | -29.7% | 52,328 | -10.7% | 0.00% | -100.0% |
| Q2 2023 | $585,185 | +140.5% | 58,577 | +113.8% | 0.00% | – |
| Q1 2023 | $243,312 | -19.1% | 27,400 | +0.0% | 0.00% | – |
| Q4 2022 | $300,753 | -20.0% | 27,391 | -5.1% | 0.00% | – |
| Q3 2022 | $376,000 | +90.9% | 28,850 | +84.7% | 0.00% | – |
| Q2 2022 | $197,000 | -3.0% | 15,619 | +7.9% | 0.00% | – |
| Q1 2022 | $203,000 | -48.7% | 14,474 | +5.7% | 0.00% | – |
| Q4 2021 | $396,000 | -3.6% | 13,695 | -0.0% | 0.00% | – |
| Q3 2021 | $411,000 | +50.5% | 13,698 | +32.8% | 0.00% | – |
| Q2 2021 | $273,000 | -10.8% | 10,313 | +5.0% | 0.00% | – |
| Q1 2021 | $306,000 | -47.6% | 9,826 | -44.7% | 0.00% | – |
| Q4 2020 | $584,000 | – | 17,782 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |